Aimmune Therapeutics (AIMT) Misses Q4 EPS by 4c

Aimmune Therapeutics (NASDAQ: AIMT) reported Q4 EPS of ($0.39), $0.04 worse than the analyst estimate of ($0.35).

For earnings history and earnings-related data on Aimmune Therapeutics (AIMT) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22